{"id":399237,"date":"2025-06-03T01:05:00","date_gmt":"2025-06-02T23:05:00","guid":{"rendered":"https:\/\/medizinonline.com\/creme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse\/"},"modified":"2025-06-03T02:46:16","modified_gmt":"2025-06-03T00:46:16","slug":"creme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/creme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse\/","title":{"rendered":"Cr\u00e8me au delgocitinib &#8211; premier inhibiteur topique pan-JAK autoris\u00e9 en Suisse"},"content":{"rendered":"\n<p><strong>Dans les \u00e9tudes de phase III DELTA 1 et 2, la cr\u00e8me de degocitinib a montr\u00e9 une efficacit\u00e9 rapide &#8211; \u00e0 la semaine 16, la moiti\u00e9 des patients ont obtenu une am\u00e9lioration de 75% de l&#8217;HECSI. Les r\u00e9sultats de l&#8217;\u00e9tude de prolongation DELTA 3 montrent que les effets du traitement sont stables dans le temps et que le profil b\u00e9n\u00e9fice\/risque est bon, m\u00eame en cas d&#8217;utilisation prolong\u00e9e. La cr\u00e8me de delgocitinib est approuv\u00e9e pour tous les sous-types d&#8217;ecz\u00e9ma chronique des mains chez l&#8217;adulte, lorsque les corticost\u00e9ro\u00efdes topiques ne sont pas suffisants ou ne conviennent pas. Il s&#8217;agit d&#8217;une option th\u00e9rapeutique innovante qui r\u00e9pond \u00e0 une lacune importante dans le traitement.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fcreme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Dans les \u00e9tudes de phase III DELTA 1 et 2, la cr\u00e8me de degocitinib a montr\u00e9 une efficacit\u00e9 rapide &#8211; \u00e0 la semaine 16, la moiti\u00e9 des patients ont obtenu&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fcreme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":399239,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Ecz\u00e9ma chronique des mains mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re  ","footnotes":"[{\"id\":\"5fd2a9ab-47f8-4f7b-8739-58f8744c9e42\",\"content\":\"Des sympt\\u00f4mes au moins l\\u00e9gers \\u00e9taient d\\u00e9finis par le score IGA-CHE dans l'\\u00e9tude DELTA-3. Pour un IGA-CHE de 0\\\/1, la peau est consid\\u00e9r\\u00e9e comme (presque) exempte de sympt\\u00f4mes et \\u00e0 partir d'un IGA-CHE \\u22652, le traitement 2\\u00d7\\\/jour a \\u00e9t\\u00e9 repris. \"},{\"id\":\"112fccc4-666b-4cb5-94e3-44b2c55f867d\",\"content\":\"Des diff\\u00e9rences statistiquement significatives dans l'am\\u00e9lioration du HESD (Hand Eczema Symptom Diary) pour les d\\u00e9mangeaisons et la douleur par rapport \\u00e0 la ligne de base ont \\u00e9t\\u00e9 observ\\u00e9es avec Anzupgo\\u00ae par rapport \\u00e0 la cr\\u00e8me v\\u00e9hicule pour une r\\u00e9duction moyenne des d\\u00e9mangeaisons d\\u00e8s le jour 1 (0,75 vs 0,32 ; p&lt;0,001) et pour une r\\u00e9duction moyenne de la douleur au jour 3 (0,98 vs 0,58 ; p=0,001).\"},{\"id\":\"2738cdf8-0433-434b-8a42-265c4d498549\",\"content\":\"La proportion de patients pr\\u00e9sentant une r\\u00e9ponse HECSI-75 et la proportion de patients pr\\u00e9sentant une r\\u00e9duction de l'HESD pour le prurit\\\/la douleur de \\u22654 points ont \\u00e9t\\u00e9 maintenues dans DELTA 3 jusqu'\\u00e0 la semaine 52.\"},{\"id\":\"9987b0b2-5898-410e-8b16-3882ad83cd2c\",\"content\":\"Le profil de s\\u00e9curit\\u00e9 d'Anzupgo\\u00ae a \\u00e9t\\u00e9 \\u00e9valu\\u00e9 dans trois \\u00e9tudes cliniques jusqu'\\u00e0 16 semaines (DELTA 1&amp;2) ou 52 semaines (DELTA 3). Le profil de s\\u00e9curit\\u00e9 d'Anzupgo\\u00ae est coh\\u00e9rent et comparable \\u00e0 celui de la cr\\u00e8me v\\u00e9hicule, aussi bien \\u00e0 la semaine 16 dans DELTA 1&amp;2 que jusqu'\\u00e0 la semaine 52 dans DELTA 3.      \"}]"},"category":[11349,11362,11531,11428,11545,11464,11549],"tags":[82474,82475,19726,20601,15569,17644],"powerkit_post_featured":[],"class_list":["post-399237","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergologie-et-immunologie-clinique","category-dermatologie-et-venerologie","category-formation-continue","category-infectiologie","category-marche-medecine","category-pharmacologie-et-toxicologie","category-rx-fr","tag-anpgo","tag-creme-au-delgocitinib","tag-delta-fr","tag-eczema-des-mains","tag-inhibiteur-de-jak","tag-staphylococcus-aureus-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-06 15:20:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":399197,"slug":"delgocitinib-crema-primo-inibitore-pan-jak-topico-autorizzato-in-svizzera","post_title":"Delgocitinib crema - primo inibitore pan-JAK topico autorizzato in Svizzera","href":"https:\/\/medizinonline.com\/it\/delgocitinib-crema-primo-inibitore-pan-jak-topico-autorizzato-in-svizzera\/"},"pt_PT":{"locale":"pt_PT","id":399243,"slug":"delgocitinib-creme-primeiro-inibidor-topico-pan-jak-autorizado-na-suica","post_title":"Delgocitinib creme - primeiro inibidor t\u00f3pico pan-JAK autorizado na Su\u00ed\u00e7a","href":"https:\/\/medizinonline.com\/pt-pt\/delgocitinib-creme-primeiro-inibidor-topico-pan-jak-autorizado-na-suica\/"},"es_ES":{"locale":"es_ES","id":399196,"slug":"crema-de-delgocitinib-primer-inhibidor-topico-pan-jak-autorizado-en-suiza","post_title":"Crema de delgocitinib: primer inhibidor t\u00f3pico pan-JAK autorizado en Suiza","href":"https:\/\/medizinonline.com\/es\/crema-de-delgocitinib-primer-inhibidor-topico-pan-jak-autorizado-en-suiza\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/399237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=399237"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/399237\/revisions"}],"predecessor-version":[{"id":402183,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/399237\/revisions\/402183"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/399239"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=399237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=399237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=399237"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=399237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}